Reversal to Normoglycemia by Treating Prediabetes
NCT07392151 on ClinicalTrials.gov · last registry update 2026-02-06
A small phase 3 — 158 participants, against a typical 424. Due to report October 2029, alongside 7 other tracked readouts that quarter. Primary outcome, as filed: Presence of a composite of retinopathy, nephropathy, neuropathy, and MASLD. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for prediabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Michael Mæng
- Sponsor type
- Other
- Enrollment
- 158
- Started
- 2026-02
- Primary completion
- 2029-10 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Presence of a composite of retinopathy, nephropathy, neuropathy, and MASLD
Conditions studied
Prediabetes · Chronic Coronary Syndrome
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.